Cladribine is part of a wider trend in the NHS toward embracing time-saving innovations. Similar treatments, such as the ...

Thousands of NHS patients in England with multiple sclerosis (MS) will soon be offered a "take at home" tablet to manage ...

The medication, which will be rolled out to patients with relapsing-remitting MS, is thought to be the first in Europe to be ...

Thousands of NHS patients in England with multiple sclerosis (MS) are set to benefit from a life-changing ‘take at home’ tablet, as the NHS becomes the first healthcare system in Europe to roll it out ...

The Scottish Medicines Consortium is reviewing cladribine for broader use in relapsing forms of the condition.

Cladribine is rapidly absorbed with maximum concentration reached 30–50 min after oral administration and 0–20% bound to plasma protein. The half-life varies from 5.6 to 7.6 h and 18.4 to 19.7 ...

The National Institute for Health and Care Excellence (NICE) has recommended cladribine (Mavenclad, Merck Serono) for adults in England with relapsing-remitting multiple sclerosis (RRMS).

A take-at-home tablet for multiple sclerosis (MS) is set to be more broadly rolled out on the NHS, potentially benefiting ...

“Broadening access to cladribine means thousands more patients will benefit from managing their treatment at home rather than regularly attending hospital appointments – as well giving women with MS ...

The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...

The health service is thought to be the first in Europe to widely rollout cladribine, also known as Mavenclad and made by Merck. It has been approved by the National Institute for Health and Care ...